Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioCardiaBCDA +2.78%23 3-Year EPS without NRI Growth Rate is 50.40% as of Jun. 2026, which is 38% above its 10-year median of 36.60. GuruFocus rates BCDA with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 1,160 Biotechnology companies, BioCardia ranks better than 85% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 50.40% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 41.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of BioCardia was 67.80% per year. The lowest was -44.60% per year. And the median was 36.60% per year.
BioCardia (NAS:BCDA) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
BioCardia 3-Year EPS without NRI Growth Rate Related Terms
BCDA vs ZIVO, CYCN, LPCN: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, BioCardia's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioCardia 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioCardia's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where BioCardia's 3-Year EPS without NRI Growth Rate falls into.
BioCardia 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 50.40% mean?
BioCardia (BCDA) has a 3-Year EPS without NRI Growth Rate of 50.40% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for BioCardia and its competitors. This is 38% above median its historical median of 36.60. According to the industry distribution chart, BioCardia ranks #174 out of 1160 companies in the Biotechnology industry, placing it in the top 15%.
Is BioCardia's 3-Year EPS without NRI Growth Rate too high?
BioCardia's current 3-Year EPS without NRI Growth Rate of 50.40% is 38% above median its 10-year median of 36.60. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.05. BioCardia's value of 50.40% is 214% above this industry median. Based on the distribution chart, BioCardia ranks #174 out of 1160 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioCardia has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does BioCardia's 3-Year EPS without NRI Growth Rate compare to ZIVO and CYCN?
According to the Biotechnology industry distribution chart, BioCardia ranks #174 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This places BioCardia in the top 15% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 16.05. BioCardia's value of 50.40% is 214% above this benchmark. While the company's 10-year median is 36.60 vs. the industry median of 16.05, BioCardia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.05, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioCardia's current 3-Year EPS without NRI Growth Rate of 50.40% is 214% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for BioCardia and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioCardia's current 3-Year EPS without NRI Growth Rate is 50.40%, which is 38% above median its own 10-year median of 36.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioCardia stock overvalued right now?
BioCardia (BCDA) has a current 3-Year EPS without NRI Growth Rate of 50.40%. The current 3-Year EPS without NRI Growth Rate is 50.40%, which is 38% above median its 10-year median of 36.60 and 214% above the Biotechnology industry median of 16.05. BioCardia's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For BioCardia (BCDA), the current 3-Year EPS without NRI Growth Rate is 50.40% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
23GF Score
Get the complete analysis for BCDA
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BCDA has been successfully added to your 
